In ER-negative/PR-positive ERBB2-negative BC, a recent retrospective study32 found that patients who receive adjuvant endocrine therapy have statistically significantly longer relapse-free survival and OS than patients who do not receive endocrine therapy. This evidence concerns the gene ESR1 and breast cancer.